Advertisement

Molecular diagnostics firm Metamark Genetics Inc. has named Peter Blume-Jensen as chief scientific officer of the company.

With a history in personalized oncology medicine, Blume-Jensen has worked most recently as executive director of external scientific affairs and vice president at the Daiichi Sankyo Research Institute of Daiichi Sankyo Inc. He previously served as department head at EMD Serono Inc., as well as at Merck Research Laboratories, Merck & Co., the parent company of EMD Serono.

SOURCE

Advertisement
Advertisement